ClearPoint Neuro, Inc. - CLPT STOCK NEWS

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the upcoming retirement of John N. Spencer, Jr. from its Board of Directors, effective at the Annual Meeting of Stockholders on June 3, 2021. Spencer has served since March 2010 and is credited with substantially contributing to the company's growth. ClearPoint has achieved significant milestones, including nearing its 5,000th case, and holds a preeminent status in the medical device sector. The company provides innovative solutions for neurological disorders.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announces that uniQure N.V. has completed patient enrollment for the first dose cohort of a randomized Phase I/II clinical trial of AMT-130 for early-stage Huntington's disease. Six of ten patients received AMT-130 using ClearPoint's navigation systems. A second cohort with 16 patients is set to enroll in late 2021, along with a Phase Ib/II trial planned in Europe. Huntington's disease affects ~70,000 individuals in the U.S. and Europe, with no approved therapies currently available for its progression.

ClearPoint Neuro (CLPT) announced the appointment of Ellisa Cholapranee as General Counsel, effective April 5, 2021. Reporting to CEO Joe Burnett, Cholapranee brings nearly a decade of legal experience in the life sciences and medical device sectors. Her expertise in compliance, strategy, and partnerships is expected to enhance the company's operations, especially in gene therapy and drug delivery agreements. The company continues to innovate in neurological disorder treatments, with its ClearPoint Neuro Navigation System already installed in over 60 clinical sites.

ClearPoint Neuro reports a 16% revenue increase to $3.7 million in Q4 2020, with full-year revenues totaling $12.8 million, up 14% from 2019. Notably, biologics and drug delivery revenues surged by 109% to $5.0 million, while functional neurosurgery revenues declined by 12% to $6.3 million due to COVID-19 challenges. The company's gross margin improved to 71%, attributed to higher service revenue. Despite a solid year, ClearPoint refrains from forecasting for 2021, citing persistent COVID-related disruptions in elective procedure volumes.

ClearPoint Neuro (Nasdaq: CLPT) has successfully closed a public stock offering, selling 2,127,660 shares, including 1,850,140 at $23.50 each and 277,520 following underwriters' options at $22.09. The net proceeds are approximately $46.8 million, which will support product development, R&D activities, and general corporate purposes. CEO Joe Burnett highlighted the strategic use of this capital to enhance the company’s capabilities in neuro-based therapies. B. Riley Securities managed the offering, with shares sold under an effective SEC registration statement.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) will release its financial results for Q4 and the full year 2020 on March 4, 2021, after market close. Investors can join a live call at 4:30 p.m. ET to discuss the results. ClearPoint specializes in neurosurgery navigation and drug delivery systems, currently having FDA clearance for its products, with installations across over 60 sites. The company is engaged with multiple biologics firms, supporting various stages of clinical trials. Forward-looking statements highlight potential impacts, including COVID-19, on future revenues and market acceptance.

ClearPoint Neuro (Nasdaq: CLPT) announced the pricing of a public offering of 1,850,140 shares of common stock at $23.50 per share, with an option for underwriters to purchase an additional 277,520 shares. The offering is set to close on February 23, 2021. Proceeds will fund product development and research, as well as general corporate purposes. B. Riley Securities is leading the offering, following SEC approval on January 29, 2021.

ClearPoint Neuro (Nasdaq: CLPT) has announced a proposed underwritten public offering of its common stock, with all shares being offered by the Company. This offering includes a 30-day option for underwriters to purchase additional shares, totaling up to 15% of the offering size. The offering is subject to market conditions, and there's no guarantee regarding its completion or terms. B. Riley Securities is the book-running manager, while Lake Street Capital Markets acts as the co-manager. The SEC has declared effective a shelf registration statement related to the offering.

ClearPoint Neuro (CLPT) announced a worldwide license and research agreement with Philips to develop the ‘Maestro™’ Brain Model, set for launch in 2022. This collaboration aims to enhance various applications in drug delivery, deep brain stimulation, laser ablation, and biopsies, enabling precise treatment paths and safer procedures. Philips' Brain Model technology, developed over 10 years, offers accurate assessments backed by extensive research. ClearPoint’s products are FDA cleared and used in over 60 clinical sites across the U.S., Canada, and Europe, supporting a diverse range of neurological therapies.